Inventor · disambiguated record
Lukas Scheibler
Also filed as: SCHEIBLER LUKAS · SCHEIBLER LUKAS CHRISTOPH
22 granted patents·14 pending applications·179 citations·filing 2002–2025
95Inventor score
Top patents by PatentIndex Score
36 records- 0199US10952607B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2020·Granted Mar 23, 2021·17 cites·23 claims
- 0298US11627874B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2021·Granted Apr 18, 2023·7 cites·22 claims
- 0398US11576572B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2022·Granted Feb 14, 2023·9 cites·24 claims
- 0498US11357401B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2020·Granted Jun 14, 2022·13 cites·25 claims
- 0597US11896308B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2022·Granted Feb 13, 2024·3 cites·22 claims
- 0697US11890053B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2023·Granted Feb 6, 2024·3 cites·22 claims
- 0796US10610096B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2018·Granted Apr 7, 2020·34 cites·23 claims
- 0892US6730319B2Pharmaceutical compositions having depressed melting pointsHOFFMANN LA ROCHE·Filed 2002·Granted May 4, 2004·71 cites·28 claims
- 0990US11147855B2Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humourCELLA THERAPEUTICS LLC·Filed 2019·Granted Oct 19, 2021·3 cites·19 claims
- 1090US2025339023A1Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2025·Application pending·0 cites
- 1189US10159566B2Heat tunable intraocular lensNOVARTIS AG·Filed 2016·Granted Dec 25, 2018·10 cites·12 claims
- 1287US2025352328A1Heat tunable intraocular lensALCON INC·Filed 2025·Application pending·0 cites
- 1386US12396639B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 1486US9604949B2Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertensionNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·5 cites·12 claims
- 1585US12128104B2Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2020·Granted Oct 29, 2024·1 cites·17 claims
- 1685US11510939B1RNAs for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 29, 2022·1 cites·16 claims
- 1784US12290317B2Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2023·Granted May 6, 2025·0 cites·20 claims
- 1880US12396843B2Heat tunable intraocular lensALCON INC·Filed 2023·Granted Aug 26, 2025·0 cites·12 claims
- 1980US2025235097A1Miniaturized mobile, low cost optical coherence tomography system for home based ophthalmic applicationsACUCELA INC·Filed 2025·Application pending·0 cites
- 2079US2025090670A1Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 2178US12251395B2RNAS for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Granted Mar 18, 2025·0 cites·7 claims
- 2277US2023158161A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 2374US2022339237A1Drug delivery systems comprising an intraocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 2472US2021121534A1Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertensionCELLA THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 2569US11666432B2Heat tunable intraocular lensALCON INC·Filed 2020·Granted Jun 6, 2023·0 cites·11 claims
- 2666US8039508B2Lipase inhibiting compositionHOFFMANN LA ROCHE·Filed 2004·Granted Oct 18, 2011·2 cites·62 claims
- 2764US2024216538A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2864US2025002910A1Treatment of complement-mediated disordersAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2961US10786348B2Heat tunable intraocular lensNOVARTIS AG·Filed 2018·Granted Sep 29, 2020·0 cites·17 claims
- 3061US2024110182A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3156US8343543B2Lipase inhibiting compositionHOFFMANN LA ROCHE·Filed 2011·Granted Jan 1, 2013·0 cites·19 claims
- 3253US10016441B2Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertensionNOVARTIS AG·Filed 2017·Granted Jul 10, 2018·0 cites·4 claims
- 3353US2022249706A1Viral vector therapyAPELLIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3452US2023094423A1Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitorCELLA THERAPEUTICS LLC·Filed 2020·Application pending·0 cites
- 3551US2022280598A1Complement inhibitor dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3648US2025145673A1Polypeptides for complement inhibitionAFFILOGIC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lukas Scheibler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →